{
  "alleleExist":false,
  "dataVersion":"v4.5",
  "diagnosticImplications":[],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"BCL10, a tumor suppressor and pro-apoptotic protein, is infrequently altered in cancer.",
  "highestDiagnosticImplicationLevel":null,
  "highestFdaLevel":null,
  "highestPrognosticImplicationLevel":null,
  "highestResistanceLevel":null,
  "highestSensitiveLevel":null,
  "hotspot":false,
  "lastUpdate":"02/27/2019",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[
        "9989495",
        "10319863"
      ]
    },
    "description":"Truncating mutations of BCL10 occur either within or C-terminal to the CARD domain of the protein. Experimental studies have shown that mutations within the CARD domain cannot induce cell death or activate NF-kB signaling. In contrast, mutations after the CARD domain, while retaining NF-kB signaling, failed to induce apoptosis (PMID: 9989495, 10319863).",
    "knownEffect":"Likely Loss-of-function"
  },
  "oncogenic":"Likely Oncogenic",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[],
  "prognosticSummary":"",
  "query":{
    "alteration":"I46Yfs*24",
    "alterationType":null,
    "consequence":"frameshift_variant",
    "entrezGeneId":8915,
    "hgvs":null,
    "hugoSymbol":"BCL10",
    "id":null,
    "proteinEnd":46,
    "proteinStart":46,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[],
  "tumorTypeSummary":"",
  "variantExist":false,
  "variantSummary":"The BCL10 I46Yfs*24 mutation is likely oncogenic.",
  "vus":false
}